Anthocyanins increase serum adiponectin in newly diagnosed diabetes but not in prediabetes: a randomized controlled trial

Liping Yang, Wenhua Ling, Yun Qiu, Yong Liu, Li Wang, Jing Yang, Changyi Wang, Jianping MaResearch Square 2020 · DOI

TL;DR

A 12-week randomized controlled trial found that daily supplementation with 320 mg of purified anthocyanins significantly increased serum adiponectin and lowered fasting glucose in patients with newly diagnosed type 2 diabetes. Interestingly, these metabolic benefits did not extend to individuals with prediabetes, suggesting that the therapeutic window for anthocyanins may depend on the specific stage of disease progression.

What Problem Does This Paper Address?

Type 2 diabetes mellitus (T2DM) is a global health crisis, often preceded by a state of prediabetes. Central to this progression is adiponectin, the most abundant hormone secreted by fat tissue (an "adipokine"). Adiponectin is a metabolic "good guy"—it enhances insulin sensitivity, fights inflammation, and protects blood vessels. Low levels of adiponectin are a known risk factor for developing T2DM.

While previous studies suggested that anthocyanins—the vibrant pigments found in blueberries, grapes, and purple corn—could improve lipid profiles, evidence regarding their effect on adiponectin was inconsistent. Furthermore, it was unclear if these plant compounds could help patients before they require heavy medication. This study sought to determine if purified anthocyanins could boost adiponectin levels in two critical early-stage groups: those with prediabetes and those with newly diagnosed, untreated T2DM.

Methods

The researchers conducted a 12-week, randomized, double-blind, placebo-controlled trial in Guangzhou, China.

  • Participants: 160 individuals (90 with prediabetes, 70 with newly diagnosed T2DM).
  • Intervention: The treatment group received 320 mg/day of purified anthocyanins (as Medox capsules), while the control group received an identical-looking placebo.
  • Measurements: The team tracked serum adiponectin using ELISA, alongside a battery of biomarkers including fasting glucose (via a 3-hour oral glucose tolerance test), HbA1c, and lipid profiles (apolipoproteins A-1 and B).
  • Control: Participants were instructed to maintain their usual diet and physical activity but specifically avoid anthocyanin-rich foods (like berries and grapes) to prevent confounding results.

Datasets

As a clinical trial, the primary "dataset" consisted of the clinical and demographic data from the 160 recruited participants. After accounting for dropouts and compliance issues, the final analysis was performed on 138 patients. The study also referenced previous meta-analyses and clinical trials to establish its sample size and power calculations.

Key Insights and Ideas

  • The "Stage-Dependent" Effect: The most striking finding was the divergence in results. Anthocyanins worked for the diabetics but not the prediabetics. The authors hypothesize that because prediabetics have a "lower hyperglycemic status," their metabolic systems might be less responsive to the specific pathways anthocyanins trigger.
  • Preventing the Decline: In the diabetic placebo group, adiponectin levels actually decreased over the 12 weeks, representing the natural progression of the disease. The anthocyanin intervention didn't just "increase" levels in a vacuum; it effectively halted and reversed this downward trend.
  • Lipid Improvements Across the Board: While the adiponectin effect was group-specific, the anthocyanins improved apolipoprotein profiles (increasing Apo A-1 and decreasing Apo B) in both the prediabetic and diabetic groups, suggesting broader cardiovascular benefits regardless of glucose status.
  • Molecular Mechanisms: The paper points to the activation of AMPK (a master regulator of energy metabolism) and PPARα as the likely drivers behind the increased adiponectin secretion and improved glucose uptake.

Key Results

  • Adiponectin Boost: In the newly diagnosed diabetes group, anthocyanins led to a significant net increase in serum adiponectin of 0.46 µg/mL (p=0.038) compared to the placebo.
  • Glucose Reduction: The same group saw a significant drop in fasting glucose of -0.5 mmol/L (p=0.035).
  • Prediabetes Null Result: No significant change in adiponectin (net change -0.35 µg/mL, p=0.174) or fasting glucose was observed in the prediabetes group.
  • Safety: The intervention was well-tolerated, with no significant difference in adverse events between the anthocyanin and placebo groups.

Limitations and Future Work

The authors acknowledge several hurdles:

  1. Blinding Challenges: The placebo and anthocyanin capsules had different internal contents, which might have led to the higher dropout rate in the placebo group if participants suspected they weren't on the "active" treatment.
  2. Compliance Monitoring: There was no objective measure (like a blood test for anthocyanin metabolites) to verify that participants actually took the supplements; they relied on capsule counts and diaries.
  3. Total vs. HMW Adiponectin: The study measured total adiponectin. However, high-molecular-weight (HMW) adiponectin is often considered the more biologically active form. Future studies should distinguish between these fractions.
  4. Long-term Efficacy: 12 weeks is a short window. Longer-term studies are needed to see if these changes translate into a lower risk of diabetic complications or a delay in the need for pharmacological intervention.

Summary updated

Abstract

<title>Abstract</title> <bold>Background </bold>Epidemiological studies have suggested that adiponectin is associated with the development of insulin resistance and type 2 diabetes. This study first examined the effect of purified anthocyanins, a group of dietary flavonoids, on serum adiponectin in patients with prediabetes and newly diagnosed diabetes.<bold>Methods </bold>A total of 160 patients with prediabetes (n=90) or newly diagnosed diabetes (n=70) were randomly assigned to either the anthocyanins group or the placebo group for 12 weeks of intervention. Serum adiponectin, a set of biomarkers related to glucolipid metabolism, anthropometric parameters, dietary intake and physical activity were measured before and after intervention.<bold>Results </bold>Anthocyanins increased serum adiponectin compared with placebo (net change 0.46 µg/mL, 95% CI [0.03, 0.90], <italic>p</italic>=0.038) in the subjects with newly diagnosed diabetes. No significant difference in the change in adiponectin was observed between the two groups either in the overall subjects (0.02 µg/mL [-0.32, 0.36], <italic>p</italic>=0.906) or in prediabetes (-0.35 µg/mL [-0.85, 0.16], <italic>p</italic>=0.174). Anthocyanins also decreased fasting glucose (-0.5 mmol/L [-1, -0.04], <italic>p</italic>=0.035) in the subjects with newly diagnosed diabetes, but no such change was observed in those with prediabetes.<bold>Conclusions </bold>Anthocyanins supplementation for 12 weeks improved serum adiponectin and fasting glucose in patients with newly diagnosed diabetes, but not in patients with prediabetes.
BibTeX
@inproceedings{yang2020anthocyanins,
  author = {Liping Yang and Wenhua Ling and Yun Qiu and Yong Liu and Li Wang and Jing Yang and Changyi Wang and Jianping Ma},
  title = {{Anthocyanins increase serum adiponectin in newly diagnosed diabetes but not in prediabetes: a randomized controlled trial}},
  booktitle = {Research Square},
  year = {2020},
  doi = {10.21203/rs.3.rs-28039/v2},
}
Figure